指南与共识支持与姑息治疗

ASCO临床实践指南更新:癌症患者静脉血栓栓塞的预防与治疗

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.
指南 / 共识 · J Clin Oncol · 2019-08-05

更新包括:高风险的选定的门诊患者可接受阿哌沙班、利伐沙班或低分子肝素(LMWH)血栓预防;利伐沙班和依度沙班新增为VTE治疗选项;脑转移患者纳入VTE治疗部分;术后长期LMWH推荐范围扩大。重申推荐:多数因急性内科疾病住院的癌症患者需全程血栓预防;不常规推荐所有门诊患者血栓预防;大手术患者术前开始预防并持续至少7-10天;应定期评估VTE风险并提供患者教育。

要点

  • 高风险的选定的门诊癌症患者可考虑阿哌沙班、利伐沙班或LMWH进行血栓预防。
  • 利伐沙班和依度沙班可作为癌症患者VTE治疗的选项。
  • 大手术患者术前开始预防并持续至少7-10天,不常规推荐所有门诊患者预防。

核心结论

  • 更新了癌症患者VTE预防和治疗的推荐,包括门诊高危患者预防、DOACs治疗选项、脑转移患者管理及术后长期LMWH推荐扩展。

主要发现

  • 两项DOACs治疗癌症患者VTE的随机对照试验报告,依度沙班和利伐沙班有效,但与LMWH相比,在胃肠道和潜在泌尿生殖系统癌症患者中出血风险更高。
  • 另外两项随机对照试验报告了DOACs用于VTE风险增加的门诊癌症患者的血栓预防。

关键数值与推荐

  • 临床医生可为选定的高风险门诊癌症患者提供阿哌沙班、利伐沙班或LMWH血栓预防。
  • 利伐沙班和依度沙班已新增为VTE治疗选项。
  • 脑转移患者现已在VTE治疗部分中涉及。
  • 关于术后长期LMWH的推荐已扩展。
  • 多数因急性内科疾病住院的癌症患者需在整个住院期间进行血栓预防。

临床怎么用

  • 对选定的高风险门诊癌症患者可考虑DOACs或LMWH进行血栓预防。
  • VTE治疗可选择利伐沙班或依度沙班,但需注意胃肠道和潜在泌尿生殖系统癌症患者的出血风险。
  • 大手术患者术前开始预防并持续至少7-10天,住院患者全程预防。
  • 定期评估VTE风险并提供患者教育。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To provide updated recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer. METHODS: PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs published from August 1, 2014, through December 4, 2018. ASCO convened an Expert Panel to review the evidence and revise previous recommendations as needed. RESULTS: The systematic review included 35 publications on VTE prophylaxis and treatment and 18 publications on VTE risk assessment. Two RCTs of direct oral anticoagulants (DOACs) for the treatment of VTE in patients with cancer reported that edoxaban and rivaroxaban are effective but are linked with a higher risk of bleeding compared with low-molecular-weight heparin (LMWH) in patients with GI and potentially genitourinary cancers. Two additional RCTs reported on DOACs for thromboprophylaxis in ambulatory patients with cancer at increased risk of VTE. RECOMMENDATIONS: Changes to previous recommendations: Clinicians may offer thromboprophylaxis with apixaban, rivaroxaban, or LMWH to selected high-risk outpatients with cancer; rivaroxaban and edoxaban have been added as options for VTE treatment; patients with brain metastases are now addressed in the VTE treatment section; and the recommendation regarding long-term postoperative LMWH has been expanded. Re-affirmed recommendations: Most hospitalized patients with cancer and an acute medical condition require thromboprophylaxis throughout hospitalization. Thromboprophylaxis is not routinely recommended for all outpatients with cancer. Patients undergoing major cancer surgery should receive prophylaxis starting before surgery and continuing for at least 7 to 10 days. Patients with cancer should be periodically assessed for VTE risk, and oncology professionals should provide patient education about the signs and symptoms of VTE.Additional information is available at www.asco.org/supportive-care-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2019. PMID: 31381464. doi:10.1200/JCO.19.01461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。